Top Industry Leaders in the Glioblastoma Multiforme Market
In December 2022, the FDA granted Fast Track designation to WP1122, a novel glioblastoma treatment developed by Wolf Pharmaceuticals. This designation expedites the review process for promising new drugs, potentially bringing WP1122 to market sooner.
In November 2023, the China National Medical Products Administration (NMPA) granted marketing approval for the Optune device from NovoCure. This non-invasive therapy uses tumor treating fields (TTF) to disrupt cancer cell division and is a valuable addition to the treatment landscape for GBM patients in China.
In October 2023, Roche announced positive Phase 2 results for RO7499870, a targeted therapy aimed at a specific genetic mutation found in some GBM tumors. These results pave the way for further development of this promising treatment candidate.
List of Glioblastoma Multiforme Key Companies in the Market
- Merck & Co., Inc (US)
- Amgen, Inc (US)
- Bristol-Myers Squibb Company (US)
- Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Pfizer Inc (US)
- AstraZeneca (UK)
- Eli Lilly and Company (US)
- VBI Vaccines Inc. (US)
- AbbVie Inc. (US)
